Valion Bio Enters Letter Agreement for 4,717.73 Series C Preferred Shares
Valion Bio and purchasers entered a letter agreement for 4,717.73 Series C preferred shares on Oct. 26, 2026.
Related stories
KBR Reports Quarterly Results for Period Ended September 30
KBR reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Alphabet Shares Fall 12%
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Oshkosh Reports Q3 Earnings Below Estimates, Cuts 2026 EPS Guidance
Oshkosh reported adjusted Q3 2026 EPS of $2.41 versus the $3.06 FactSet consensus and revenue of $2.84 billion versus $2.94 billion. It lowered 2026 GAAP EPS guidance to $8.00-$9.0
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Entegris Reports Q3 Revenue of $1.005 Billion, Issues Q4 Outlook
Third-quarter revenue rose 24.5% year over year to $1.005 billion. GAAP earnings were $157.8 million, or $1.03 per share; adjusted earnings were $189.7 million, or $1.23 per share.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Leonardo DRS Q3 Revenue Rises 11%; Raises 2026 Guidance
Revenue was $1.1 billion and net earnings rose 60% to $115 million. Adjusted diluted EPS increased 59% to $0.46; bookings were $1.6 billion, with a 1.5x book-to-bill ratio and reco
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Harley-Davidson Reports Q3 Results, Raises 2026 Guidance
Harley-Davidson reported Q3 2026 results, including a 9% year-over-year increase in North American retail sales of new motorcycles. It raised full-year guidance for both HDMC and H
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC